Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer The FDA initially approved Keytruda in 2017 for stomach cancer based on overall response rate data. ... Among these, Keytruda achieved an overall response rate of just over 13% (19 patients), with a complete response rate of 1.4%.

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies Instead of targeting a specific genetic defect, Keytruda targets tumours that have a high degree of genetic instability. ... As Vitrakvi and Rozlytrek lead with their TA indications, the challenges faced by these therapies are wholly different to Keytruda

Merck’s Keytruda improves outcomes for metastatic cervical cancer patients

Merck’s Keytruda improves outcomes for metastatic cervical cancer patients Keytruda improved overall survival and progression-free survival regardless of patients' PD-L1 status. ... Merck – known as MSD outside the US and Canada – has revealed positive results for its checkpoint inhibitor Keytruda in patients with persistent

Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients

Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients Merck &Co – known as MSD outside the US and Canada – has announced that its PD-1 inhibitor Keytruda plus Eisai’s Lenvima improved outcomes versus Pfizer’s Sutent on a measure ... When administered alongside Lenvima, Keytruda demonstrated a

Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients

Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients dominant shadow of Merck &Co’s Keytruda (pembrolizumab).

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...